GAGE2D Inhibitors
Inhibitors of GAGE2D function by targeting various signaling pathways and cellular processes to reduce the protein's activity or expression. For instance, some compounds may interfere with the mTOR pathway, which is crucial for protein synthesis and cell proliferation. By doing so, they create a cellular environment that is less conducive to the expression of GAGE2D, leading to its decreased levels. Other inhibitors target the chromatin remodeling process by inhibiting histone deacetylases, which may result in a more compact chromatin state and a consequent reduction in the transcription of genes like GAGE2D. Additionally, phosphoinositide 3-kinase (PI3K) inhibitors can disrupt critical survival and growth signaling pathways, such as the PI3K/AKT pathway, leading to a diminution in GAGE2D levels.
Furthermore, the MAPK/ERK pathway, which is implicated in the regulation of numerous proteins, can be modulated by specific inhibitors that prevent the activation of MEK, consequently reducing the expression or stability of GAGE2D. Proteasome inhibitors also contribute to the inhibition of GAGE2D by causing an accumulation of misfolded proteins, which could lead to a cellular environment that preferentially targets GAGE2D for degradation. Inhibition of other kinases such as JNK, p38 MAPK, CRAF, and EGFR tyrosine kinase also plays a role in diminishing the signaling required for GAGE2D expression or activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that reduces protein synthesis and cell proliferation, which can lead to the inhibition of GAGE2D by limiting the cellular conditions necessary for its expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
A histone deacetylase inhibitor that alters chromatin structure and gene expression, decreasing the expression of GAGE2D by promoting a less permissive state for its transcription. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that disrupts the PI3K/AKT pathway, leading to reduced cell survival and growth signals that may indirectly diminish the levels of GAGE2D. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that leads to the accumulation of misfolded proteins, causing a cellular environment that degrades GAGE2D more rapidly. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
A pyrimidine analog that disrupts nucleotide synthesis, which could result in reduced expression of rapidly dividing cells' proteins, including GAGE2D. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor that interferes with the MAPK/ERK pathway, which may reduce the expression or activity of proteins like GAGE2D that are dependent on this signaling for stability. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that can modulate the JNK signaling pathway, altering the expression of GAGE2D by affecting the transcription factors that regulate its gene. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that can reduce the stress-induced expression of proteins like GAGE2D by blocking the pathway necessary for its response to cellular stress signals. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A potent inhibitor of PI3K, which may further reduce the AKT signaling, leading to decreased survival signaling and lower levels of GAGE2D. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $47.00 | 2 | |
A CRAF inhibitor that could disrupt the RAF/MEK/ERK signaling cascade, leading to a reduction in GAGE2D expression or activity due to decreased signal transduction. | ||||||